Advertisement
Screener

ATOSSA THERAPEUTICS, INC. (ATOS) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

ATOSSA THERAPEUTICS, INC. Research and Development Expense

ATOSSA THERAPEUTICS, INC. (ATOS) reported Research and Development Expense of $4.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07

  • ATOSSA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $4.90M, a 11.00% decline year-over-year.
  • ATOSSA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $4.78M, a 14.96% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $6.16M, a 80.90% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $5.37M, a 57.39% increase year-over-year.
  • ATOSSA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $21.18M, a 50.07% increase from fiscal 2024.
  • ATOSSA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $14.12M, a 18.56% decline from fiscal 2023.
  • ATOSSA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $17.33M, a 14.92% increase from fiscal 2022.
  • ATOSSA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $15.08M, a 63.77% increase from fiscal 2021.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 9 month as first filedResearch and Development Expense 12 monthResearch and Development Expense 12 month as first filedResearch and Development Expense 47 monthResearch and Development Expense 50 monthResearch and Development Expense 53 monthResearch and Development Expense 56 monthResearch and Development Expense 59 month
2026-06-30$4.90M
10-Q · filed 2026-08-07
$9.68M
10-Q · filed 2026-08-07
$15.83M
derived: sum of 3 quarters · filed 2026-08-07
$21.20M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-31$4.78M
10-Q · filed 2026-05-08
$10.94M
derived: sum of 2 quarters · filed 2026-05-08
$16.30M
derived: sum of 3 quarters · filed 2026-05-08
$21.81M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-31$6.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$11.53M
derived: sum of 2 quarters · filed 2026-03-25
$17.03M
derived: sum of 3 quarters · filed 2026-08-07
$21.18M
10-K · filed 2026-03-25
2025-09-30$5.37M
10-Q · filed 2025-11-12
$10.87M
derived: sum of 2 quarters · filed 2026-08-07
$15.03M
10-Q · filed 2025-11-12
$18.43M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-30$5.50M
10-Q · filed 2026-08-07
$9.66M
10-Q · filed 2026-08-07
$13.06M
derived: sum of 3 quarters · filed 2026-08-07
$16.47M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-31$4.16M
10-Q · filed 2026-05-08
$7.56M
derived: sum of 2 quarters · filed 2026-05-08
$10.97M
derived: sum of 3 quarters · filed 2026-05-08
$14.53M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$3.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$6.82M
derived: sum of 2 quarters · filed 2026-03-25
$10.37M
derived: sum of 3 quarters · filed 2026-03-25
$14.12M
10-K · filed 2026-03-25
2024-09-30$3.41M
10-Q · filed 2025-11-12
$6.96M
derived: sum of 2 quarters · filed 2025-11-12
$10.71M
10-Q · filed 2025-11-12
$16.37M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$3.55M
10-Q · filed 2025-08-12
$7.30M
10-Q · filed 2025-08-12
$12.96M
derived: sum of 3 quarters · filed 2025-08-12
$17.42M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$3.75M
10-Q · filed 2025-05-13
$9.40M
derived: sum of 2 quarters · filed 2025-05-13
$13.87M
derived: sum of 3 quarters · filed 2025-05-13
$17.57M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$5.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25
$10.12M
derived: sum of 2 quarters · filed 2025-03-25
$13.83M
derived: sum of 3 quarters · filed 2025-03-25
$17.33M
10-K · filed 2025-03-25
2023-09-30$4.47M
10-Q · filed 2024-11-12
$8.17M
derived: sum of 2 quarters · filed 2024-11-12
$11.68M
10-Q · filed 2024-11-12
$16.67M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$3.71M
10-Q · filed 2024-08-12
$7.21M
10-Q · filed 2024-08-12
$12.20M
derived: sum of 3 quarters · filed 2024-08-12
$17.36M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31$3.51M
10-Q · filed 2024-05-13
$8.49M
derived: sum of 2 quarters · filed 2024-05-13
$13.65M
derived: sum of 3 quarters · filed 2024-05-13
$17.09M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$4.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$10.15M
derived: sum of 2 quarters · filed 2024-04-01
$13.58M
derived: sum of 3 quarters · filed 2024-04-01
$15.08M
10-K · filed 2024-04-01
2022-09-30$5.16M
10-Q · filed 2023-11-13
$8.59M
derived: sum of 2 quarters · filed 2023-11-13
$10.10M
10-Q · filed 2023-11-13
$11.92M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$3.43M
10-Q · filed 2023-08-14
$4.94M
10-Q · filed 2023-08-14
$6.76M
derived: sum of 3 quarters · filed 2023-08-14
$8.96M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$1.50M
10-Q · filed 2023-05-15
$3.33M
derived: sum of 2 quarters · filed 2023-05-15
$5.53M
derived: sum of 3 quarters · filed 2023-05-15
$9.33M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$1.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22
$4.03M
derived: sum of 2 quarters · filed 2023-03-22
$7.83M
derived: sum of 3 quarters · filed 2023-03-22
$9.21M
10-K · filed 2023-03-22
2021-09-30$2.21M
10-Q · filed 2022-11-07
$2.21M
10-Q · filed 2021-11-15
$6.00M
derived: sum of 2 quarters · filed 2022-11-07
$7.38M
10-Q · filed 2022-11-07
$7.38M
10-Q · filed 2021-11-15
$9.74M
derived: sum of 4 quarters · filed 2022-11-07
2021-06-30$3.80M
10-Q · filed 2022-08-08
$3.80M
10-Q · filed 2021-08-13
$5.18M
10-Q · filed 2022-08-08
$5.18M
10-Q · filed 2021-08-13
$7.54M
derived: sum of 3 quarters · filed 2022-08-08
$9.19M
derived: sum of 4 quarters · filed 2022-08-08
2021-03-31$1.38M
10-Q · filed 2022-05-09
$1.38M
10-Q · filed 2021-05-14
$3.74M
derived: sum of 2 quarters · filed 2022-05-09
$5.40M
derived: sum of 3 quarters · filed 2022-05-09
$7.05M
derived: sum of 4 quarters · filed 2022-05-09
2020-12-31$2.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$4.02M
derived: sum of 2 quarters · filed 2022-02-28
$5.67M
derived: sum of 3 quarters · filed 2022-02-28
$6.61M
10-K · filed 2022-02-28
$6.61M
10-K · filed 2021-03-31
2020-09-30$1.66M
10-Q · filed 2021-11-15
$3.31M
derived: sum of 2 quarters · filed 2021-11-15
$4.25M
10-Q · filed 2021-11-15
$5.15M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30$1.65M
10-Q · filed 2021-08-13
$2.59M
10-Q · filed 2021-08-13
$3.49M
derived: sum of 3 quarters · filed 2021-08-13
$5.17M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31$938.62K
10-Q · filed 2021-05-14
$1.84M
derived: sum of 2 quarters · filed 2021-05-14
$3.52M
derived: sum of 3 quarters · filed 2021-05-14
$6.13M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31$898.02K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31
$2.58M
derived: sum of 2 quarters · filed 2021-03-31
$5.19M
derived: sum of 3 quarters · filed 2021-03-31
$6.65M
10-K · filed 2021-03-31
2019-09-30$1.68M
10-Q · filed 2020-11-13
$4.30M
derived: sum of 2 quarters · filed 2020-11-13
$5.75M
10-Q · filed 2020-11-13
$6.60M
derived: sum of 4 quarters · filed 2020-11-13
2019-06-30$2.61M
10-Q · filed 2020-08-13
$4.06M
10-Q · filed 2020-08-13
$4.91M
derived: sum of 3 quarters · filed 2020-08-13
$6.33M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31$1.45M
10-Q · filed 2020-05-13
$2.30M
derived: sum of 2 quarters · filed 2020-05-13
$3.72M
derived: sum of 3 quarters · filed 2020-05-13
$5.19M
derived: sum of 4 quarters · filed 2020-05-13
2018-12-31$849.42K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26
$2.27M
derived: sum of 2 quarters · filed 2020-03-26
$3.74M
derived: sum of 3 quarters · filed 2020-03-26
$4.21M
10-K · filed 2020-03-26
2018-09-30$1.42M
10-Q · filed 2019-11-13
$2.89M
derived: sum of 2 quarters · filed 2019-11-13
$3.36M
10-Q · filed 2019-11-13
$3.58M
derived: sum of 4 quarters · filed 2019-11-13
2018-06-30$1.47M
10-Q · filed 2019-08-13
$1.94M
10-Q · filed 2019-08-13
$2.16M
derived: sum of 3 quarters · filed 2019-08-13
$2.90M
derived: sum of 4 quarters · filed 2019-08-13
2018-03-31$470.98K
10-Q · filed 2019-05-13
$688.22K
derived: sum of 2 quarters · filed 2019-05-13
$1.43M
derived: sum of 3 quarters · filed 2019-05-13
$2.25M
derived: sum of 4 quarters · filed 2019-05-13
2017-12-31$217.24K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28
$959.69K
derived: sum of 2 quarters · filed 2019-03-28
$1.78M
derived: sum of 3 quarters · filed 2019-03-28
$2.33M
10-K · filed 2019-03-28
2017-09-30$742.45K
10-Q · filed 2018-11-14
$1.57M
derived: sum of 2 quarters · filed 2018-11-14
$2.11M
10-Q · filed 2018-11-14
$2.48M
derived: sum of 4 quarters · filed 2018-11-14
2017-06-30$824.09K
10-Q/A · filed 2018-11-13
$1.37M
10-Q/A · filed 2018-11-13
$1.73M
derived: sum of 3 quarters · filed 2018-11-13
$1.82M
derived: sum of 4 quarters · filed 2018-11-13
2017-03-31$544.30K
10-Q · filed 2018-05-14
$910.77K
derived: sum of 2 quarters · filed 2018-05-14
$995.77K
derived: sum of 3 quarters · filed 2018-05-14
$1.16M
derived: sum of 4 quarters · filed 2018-05-14
2016-12-31$366.46K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$451.46K
derived: sum of 2 quarters · filed 2018-03-08
$620.46K
derived: sum of 3 quarters · filed 2018-03-08
$770.43K
10-K · filed 2018-03-08
2016-09-30$85.00K
10-Q · filed 2017-11-13
$253.99K
derived: sum of 2 quarters · filed 2017-11-13
$403.96K
10-Q · filed 2017-11-13
$875.32K
derived: sum of 4 quarters · filed 2017-11-13
2016-06-30$168.99K
10-Q · filed 2017-08-14
$318.96K
10-Q · filed 2017-08-14
$790.32K
derived: sum of 3 quarters · filed 2017-08-14
$1.74M
derived: sum of 4 quarters · filed 2017-08-14
2016-03-31$149.97K
10-Q · filed 2017-05-11
$621.33K
derived: sum of 2 quarters · filed 2017-05-11
$1.57M
derived: sum of 3 quarters · filed 2017-05-11
$1.94M
derived: sum of 4 quarters · filed 2017-05-11
2015-12-31$471.36K
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2017-03-21
$1.42M
derived: sum of 2 quarters · filed 2017-03-21
$1.79M
derived: sum of 3 quarters · filed 2017-03-21
$2.36M
10-K/A · filed 2017-03-21
2015-09-30$948.96K
10-Q/A · filed 2017-03-21
$1.09M
10-Q · filed 2015-11-12
$1.32M
derived: sum of 2 quarters · filed 2017-03-21
$1.89M
10-Q/A · filed 2017-03-21
$2.40M
10-Q · filed 2015-11-12
$1.14M
derived: sum of 4 quarters · filed 2017-03-21
2015-06-30$373.47K
10-Q/A · filed 2017-03-21
$510.46K
10-Q · filed 2015-08-06
$939.27K
10-Q/A · filed 2017-03-21
$1.31M
10-Q · filed 2015-08-06
$193.16K
derived: sum of 3 quarters · filed 2017-03-21
$1.12M
derived: sum of 4 quarters · filed 2017-03-21
2015-03-31$565.80K
10-Q/A · filed 2017-03-21
$797.23K
10-Q · filed 2015-05-13
-$180.31K
derived: sum of 2 quarters · filed 2017-03-21
$742.86K
derived: sum of 3 quarters · filed 2017-03-21
$1.25M
derived: sum of 4 quarters · filed 2017-03-21
2014-12-31-$746.11K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
$177.06K
derived: sum of 2 quarters · filed 2016-03-30
$687.83K
derived: sum of 3 quarters · filed 2016-03-30
$1.11M
10-K · filed 2016-03-30
$2.58M
10-K · filed 2015-03-30
2014-09-30$923.17K
10-Q · filed 2015-11-12
$1.43M
derived: sum of 2 quarters · filed 2015-11-12
$1.86M
10-Q · filed 2015-11-12
$2.23M
derived: sum of 4 quarters · filed 2015-11-12
2014-06-30$510.77K
10-Q · filed 2015-08-06
$933.27K
10-Q · filed 2015-08-06
$1.31M
derived: sum of 3 quarters · filed 2015-08-06
$1.63M
derived: sum of 4 quarters · filed 2015-08-06
2014-03-31$422.50K
10-Q · filed 2015-05-13
$796.36K
derived: sum of 2 quarters · filed 2015-05-13
$1.12M
derived: sum of 3 quarters · filed 2015-05-13
$1.31M
derived: sum of 4 quarters · filed 2015-05-13
$5.08M
10-Q · filed 2014-05-14
2013-12-31$373.85K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30
$694.96K
derived: sum of 2 quarters · filed 2015-03-30
$884.92K
derived: sum of 3 quarters · filed 2015-03-30
$1.11M
10-K · filed 2015-03-30
$4.66M
10-K · filed 2014-03-27
2013-09-30$321.11K
10-Q · filed 2014-11-12
$511.07K
derived: sum of 2 quarters · filed 2014-11-12
$731.26K
10-Q · filed 2014-11-12
$1.20M
derived: sum of 4 quarters · filed 2014-11-12
$4.29M
10-Q · filed 2013-11-12
2013-06-30$189.96K
10-Q · filed 2014-08-12
$410.15K
10-Q · filed 2014-08-12
$875.22K
derived: sum of 3 quarters · filed 2014-08-12
$1.42M
derived: sum of 4 quarters · filed 2014-08-12
$3.97M
10-Q · filed 2013-08-14
2013-03-31$220.19K
10-Q · filed 2014-05-14
$685.26K
derived: sum of 2 quarters · filed 2014-05-14
$1.23M
derived: sum of 3 quarters · filed 2014-05-14
$1.78M
derived: sum of 4 quarters · filed 2014-05-14
$3.78M
10-Q · filed 2013-05-15
2012-12-31$465.07K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27
$1.01M
derived: sum of 2 quarters · filed 2014-03-27
$1.56M
derived: sum of 3 quarters · filed 2014-03-27
$1.97M
10-K · filed 2014-03-27
2012-09-30$548.11K
10-Q · filed 2013-11-12
$1.09M
derived: sum of 2 quarters · filed 2013-11-12
$1.51M
10-Q · filed 2013-11-12
2012-06-30$543.08K
10-Q · filed 2013-08-14
$961.07K
10-Q · filed 2013-08-14
2012-03-31$417.99K
10-Q · filed 2013-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Rocket One Inc. (RKTO)United States$0.019B
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
NextCure, Inc. (NXTC)United States$0.024B-0.15
Biofrontera Inc. (BFRI)United States$0.018B-2.13